Related Experiment Video
Updated: Jul 12, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
The WATCHMAN Device Review: A New Era for Stroke Prophylaxis
Samiullah Khan1, Hifza Naz2, Muhammad S Q Khan3
1Department of Cardiology, Bannu Medical College, Bannu, Pakistan.
Insights
The WATCHMAN device effectively prevents stroke in atrial fibrillation (AF) patients. Post-implantation anticoagulation strategies are crucial for managing risks like device-related thrombosis (DRT) and ensuring patient safety.
Area of Science:
- Cardiology
- Medical Devices
- Stroke Prevention
Background:
- Atrial fibrillation (AF) significantly increases ischemic stroke risk, with the left atrial appendage (LAA) being a common thrombus site.
- The WATCHMAN device offers an alternative to long-term anticoagulation for LAA closure, particularly in patients with contraindications to warfarin.
- While effective, WATCHMAN implantation carries risks including pericardial effusion, device embolization, and device-related thrombosis (DRT).
Purpose of the Study:
- To review the primary complications associated with WATCHMAN device implantation.
- To discuss optimal anticoagulation and antithrombotic strategies following WATCHMAN implantation.
- To highlight challenges in post-implantation management and treatment of complications like DRT.
Main Methods:
- Literature review of existing studies on WATCHMAN device complications and post-implantation therapies.
- Analysis of current guidelines and recent research on anticoagulation regimens.
- Discussion of diagnostic methods like transesophageal echocardiography (TEE) for monitoring.
Main Results:
- The WATCHMAN device is non-inferior to warfarin for stroke prevention in non-valvular atrial fibrillation (NVAF).
- Key complications include pericardial effusion, device embolization, procedure-related stroke, and DRT.
- Optimal post-implantation therapy requires individualized risk assessment, considering bleeding risk, DRT, and DOAC contraindications.
Conclusions:
- WATCHMAN device implantation is a safe alternative for stroke prevention in NVAF patients, but requires careful management of procedural risks.
- No universal consensus exists for post-implantation anticoagulation; individualized regimens are essential.
- Effective management involves monitoring for DRT via TEE and timely treatment with anticoagulants like LMWH or OACs.
Abstract:
Atrial fibrillation (AF) is a major risk factor for ischemic stroke, accounting for more than 37 million cases worldwide. In AF, the left atrial appendage (LAA) is the most common site of thrombus formation, and its ligation/closure with the WATCHMAN device is a good alternative to long-term oral anticoagulation, especially in patients with contraindications to warfarin. However, the implantation procedure is associated with various risks and complications. A short-term anticoagulant and antithrombotic administration are essential after implantation. However, no consensus has been reached on the optimal regimen. The WATCHMAN device is non-inferior to warfarin and is a safe alternative for the prevention of stroke and systemic embolization related to non-valvular atrial fibrillation (NVAF). Important procedure-related complications include pericardial effusion (PE), device embolization, procedure-related ischemic stroke, and device-related thrombosis (DRT) formation. It is essential to optimize post-implantation therapy according to individual patient bleeding risk, DRT formation, and contraindication to direct oral anticoagulants (DOACs). Recent studies have also shown that DOACs are a convenient and non-inferior substitute for warfarin. Furthermore, patients with absolute contraindications to OACs/DOACs can only be managed with dual antiplatelet therapy (DAPT). Transesophageal echocardiography (TEE) should be used to assess residual peridevice flow and possible DRT formation at days 45 and 12 months. Low molecular weight heparin (LMWH) and OAC are excellent choices for DRT treatment if detected. This review summarizes the most important complications of the WATCHMAN device in the existing literature and discusses various anticoagulation strategies and challenges post-implementation.
